Predicting Antimicrobial Class Specificity of Small Molecules Using Machine Learning.

Journal: Journal of chemical information and modeling
PMID:

Abstract

While the useful armory of antibiotic drugs is continually depleted due to the emergence of drug-resistant pathogens, the development of novel therapeutics has also slowed down. In the era of advanced computational methods, approaches like machine learning (ML) could be one potential solution to help reduce the high costs and complexity of antibiotic drug discovery and attract collaboration across organizations. In our work, we developed a large antimicrobial knowledge graph (AntiMicrobial-KG) as a repository for collecting and visualizing public antibacterial assay. Utilizing this data, we build ML models to efficiently scan compound libraries to identify compounds with the potential to exhibit antimicrobial activity. Our strategy involved training seven classic ML models across six compound fingerprint representations, of which the Random Forest trained on the MHFP6 fingerprint outperformed, demonstrating an accuracy of 75.9% and Cohen's Kappa score of 0.68. Finally, we illustrated the model's applicability for predicting the antimicrobial properties of two small molecule screening libraries. First, the EU-OpenScreen library was tested against a panel of Gram-positive, Gram-negative, and Fungal pathogens. Here, we unveiled that the model was able to correctly predict more than 30% of active compounds for Gram-positive, Gram-negative, and Fungal pathogens. Second, with the Enamine library, a commercially available HTS compound collection with claimed antibacterial properties, we predicted its antimicrobial activity and pathogen class specificity. These results may provide a means for accelerating research in AMR drug discovery efforts by carefully filtering out compounds from commercial libraries with lower chances of being active.

Authors

  • Yojana Gadiya
    Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, Hamburg 22525, Germany.
  • Olga Genilloud
    Fundación MEDINA, Centro de Excelencia En Investigación de Medicamentos Innovadores En Andalucía, Avenida Del Conocimiento 34, Armilla 18016, Spain.
  • Ursula Bilitewski
    Helmholtz Centre for Infection Research, Braunschweig 38124, Germany.
  • Mark Brönstrup
    Helmholtz Centre for Infection Research, Braunschweig 38124, Germany.
  • Leonie von Berlin
    Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, Hamburg 22525, Germany.
  • Marie Attwood
    PK/PD Laboratory, North Bristol, NHS Trust, Southmead Hospital, Bristol BS10 5NB, U.K.
  • Philip Gribbon
    Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, Hamburg 22525, Germany.
  • Andrea Zaliani
    Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, Hamburg 22525, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), Theodor Stern Kai 7, Frankfurt 60590, Germany. Electronic address: andrea.zaliani@itmp.fraunhofer.de.